Adalimumab-associated Bullous Pemphigoid in a Patient with Ulcerative Colitis

Bullous pemphigoid (BP) is an uncommon skin condition in which erythematous, urticarial papules and plaques progress to form tense bullae, typically in elderly men and women.1 In this disease, IgG autoantibodies are directed against hemidesmosome proteins, resulting in the formation of subepidermal vesicles.1 At least 50 drugs have been associated with BP, including the anti–tumor necrosis factor (TNF)-α drugs etanercept, infliximab, and adalimumab.2-5 Here we describe a case of suspected adalimumab-induced BP in a patient with ulcerative colitis.